Although initial clinical trials with the anti-IL-6 or -IL-6Ra monoclonal antibodies siltuximab and tocilizumab, respectively, did not reveal clinical benefits in patients with cancer as a monotherapy,52,53 such trials have not been conducted in patients with GC, nor were patients stratified for their mutational TP53 status. The gene discussed is TP53; the disease is cancer.